Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-c3 plus chemotherapy/targeted therapy in metastatic colorectal cancer
CTR20221135Phase 2Terminated
- Sponsor
- Not applicable
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azenosertib in colorectal cancer (CRC) (6 arms), sponsored by Not applicable. Primary endpoints: Objective response rate (ORR) by RECIST 1.1 in cohorts 2, 4, and 6 and Safety and dose-limiting toxicities in cohorts 1, 3, and 5. Started Jun 2022; status: terminated.
02
Drugs
azenosertib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20221135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221135.